Dr. Martin J Bury MD Hematologist

Dr. Martin Bury is a hematologist in Grand Rapids, Michigan and is affiliated with multiple hospitals in the area, including Mercy Health Saint Mary's and North Ottawa Community Hospital. He received his medical degree from Wayne State University School of Medicine and has been in practice for 33 years. Dr. Bury accepts several types of health insurance, listed below. He is one of 11 doctors at Mercy Health Saint Mary's and one of 3 at North Ottawa Community Hospital who specialize in Hematology.

Are you Dr. Bury? Edit Profile

Office Location

See Contact Information

Specialty & Clinical Interests

Hematologist: General Hematology

Hospital Affiliation

North Ottawa Community Hospital

Spectrum Health - Butterworth Hospital
High performing in Cancer

Mercy Health Saint Mary's
High performing in Cancer

Education & Medical Training

Boston University Medical Center
Residency, Internal Medicine, 1981–1982

University of Michigan Hospitals and Health Centers
Residency, Internal Medicine, 1982–1984

University of Michigan Hospitals and Health Centers
Fellowship, Hematology, 1984–1986

Wayne State University School of Medicine
Class of 1981

Certifications & Licensure

American Board of Internal Medicine
Certified in Internal Medicine

American Board of Internal Medicine
Certified in Medical Oncology

MI State Medical License
Active through 2015

Publications & Presentations

A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7.
Pruthi, S., Qin, R., Terstreip, S.A., Liu, H., Loprinzi, C.L., Shah, T.C., Tucker, K.F., Dakhil, S.R., Bury, M.J., Carolla, R.L., Steen, P.D., Vuky, J., Barton, D.L.

Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.
Gitlitz, B.J., Moon, J., Glisson, B.S., Reimers, H.J., Bury, M.J., Floyd, J.D., Schulz, T.K., Sundaram, P.K., Ho, C., Gandara, D.R.

Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial.
Hainsworth, J.D., Spigel, D.R., Clark, B.L., Shipley, D., Thompson, D.S., Farley, C., West-Osterfield, K., Lane, C.M., Cescon, T., Bury, M.J., Greco, F.A.

Insurances Accepted

  • Aetna Choice POS II
  • BCBS Blue Card PPO
  • BCBS Illinois PPO
  • CIGNA HMO
  • CIGNA Open Access
  • CIGNA PPO
  • Cofinity PPO
  • Humana ChoiceCare Network PPO
  • Multiplan PHCS PPO
  • Multiplan PPO
  • PriorityHealth HMO
  • Spectrum Health
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO

Report a Correction — If you are aware of information on this page that is out of date or incorrect, please let us know.

Patient Advice & Support


See More
Our Doctor Finder includes most U.S. physicians. Doctors are not ranked, learn more.

Nearby Hematologists

See all Hematologists near Grand Rapids, MI See all Hematologists in Michigan

Your Message Has Been Submitted

As part of our research on the correction you submitted, you may be contacted at the email address provided.

Sorry, Your Message Could Not Be Submitted

Please try again later, or E-mail your message to doctors@usnews.com and include the Web address (URL) of the page that contains incorrect information.